IPR Battles Could Become Easier For BioPharma Patent Owners
Executive Summary
En banc Federal Circuit says patent owners do not have to prove patentability of amended claims in inter partes review proceedings; judges issue five opinions in fractured decision.
You may also be interested in...
Patent Fees Increasing, Driven By Fewer Filings, Jump In PTAB Workload
US Patent and Trademark Office proposes 5% across the board patent fee adjustment plus targeted fee hikes; Patent Trial and Appeal Board costs have risen following Supreme Court's SAS Institute decision.
Court Gives Biopharma Patent Owners (A Little) Help In Inter Partes Review
In 9-4 en banc opinion, Federal Circuit finds PTAB decision that an inter partes review petition is not time-barred can be appealed; says Supreme Court left opening in Cuozzo ruling.
Congress Crafting Bill To Modify Patent Challenges In Wake Of Allergan-Mohawk Deal
House IP Subcommittee Chair Issa suggests legislation may address sovereign immunity and ways to make inter partes review process more palatable to patent owners.